CONTEXT: Report of a poster presentation at the American College of Cardiology’s 70th Annual Scientific Session on P2Y12 inhibitors, FXa inhibitors and dabigatran. Results of a retrospective analysis of claims databases revealed side-by-side comparisons of commonly prescribed therapies helping physicians to better understand bleeding risk and the potential benefits of specific treatments for their patients.
IMPACT: Medium
READ TIME: 2 mins
Quality Level Mean [1 – 10]: 7
1. “As patients treated with P2Y inhibitors had bleeding and surgery rates that often exceed the rates seen in patients treated with factor Xa inhibitors or dabigatran, PhaseBio and the authors believe this study demonstrates an unmet need for an effective reversal agent for patients prescribed P2Y inhibitors.”
2. “MALVERN, Pa. & SAN DIEGO–(BUSINESS WIRE)–PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today highlighted real-world evidence presented over the weekend at The American College of Cardiology’s 70th Annual Scientific Session.”
3. “Reversal agents that have the potential to mitigate bleeding risk exist for factor Xa inhibitors and dabigatran; however, no such agent currently exists for P2Y inhibitors.”
4. ““This analysis of real-world data highlights that the bleeding risk associated with the P2Y inhibitor class of medications is as significant as what we see with the factor Xa class of anticoagulants and dabigatran,” said Dr. Deepak L. Bhatt, M.D., M.P.H., Executive Director of Interventional Cardiovascular Programs, Brigham and Women’s Hospital Heart & Vascular Center and Professor of Medicine, Harvard Medical School.”
5. “Dr. John Lee, M.D., Ph.D., Chief Medical Officer of PhaseBio stated, “With no effective reversal agents currently approved for the P2Y inhibitor class of therapies, the extent of the bleeding risk and the subsequent impact on potentially important surgeries and procedures may be underappreciated by cardiologists, surgeons and hospital systems.”